Biotech Archives - Page 36 of 795

1 minute read

UroGen Pharma Announces Date For ENVISION Data, Long-Term Jelmyto Durability Data, To Be Discussed During Company Sponsored Virtual Event On June 13, 2024

May 13, 8:16 AM

12-month duration of response data from ENVISION study of UGN-102 to be discussed during company sponsored virtual event on June 13, 2024ENVISION data expected to support completion of UGN-102 NDA in Q3 2024Post-hoc

URGN

1 minute read

The Journal Of Clinical And Aesthetic Dermatology Published Arcutis Biotherapeutics’ Outcomes Of A Comprehensive Evaluation By An Expert Dermatologist Panel Assessing The Formulation Ingredients Of ZORYVE Topical Foam, 0.3%

By Benzinga Newsdesk

May 13, 8:08 AM

Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation

ARQT

1 minute read

Reviva To Present New Preclinical Efficacy Data On Brilaroxazine In Idiopathic Pulmonary Fibrosis At 2024 ATS International Conference In San Diego, CA, May 17-22, 2024

By Benzinga Newsdesk

May 13, 8:06 AM

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system

RVPH

1 minute read

Bristol Myers Squibb Shares Update On Phase 3 CheckMate -73L Trial; Says Trial Did Not Meet Its Primary Endpoint Of Progression-Free Survival In Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer

By Benzinga Newsdesk

May 10, 4:32 PM

Bristol Myers Squibb (NYSE:BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer

BMY

2 minute read

MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: ‘We Were Surprised By Reported Deaths’

By Vandana Singh

May 10, 3:08 PM

Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.

EXEL

2 minute read

From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing – Stocks To Watch

By Vandana Singh

May 10, 2:49 PM

Unlock the potential of AI in pharmaceuticals. With AI's help, the pharma industry could see $60B-$110B in annual economic value. Dive into the future of drug discovery and clinical development with leading players like Google, Nvidia, and Microsoft.

BAYRY

2 minute read

MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial

By Vandana Singh

May 10, 10:46 AM

Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns reported.

MGNX

2 minute read

FDA Delays ‘Important’ Moderna Vaccine Review: William Blair Says 2025 Growth, ‘2026 Breakeven Story’ Depends On It

By Vandana Singh

May 10, 9:27 AM

FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported.

GSK

2 minute read

Some Breather For Novavax’s COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern

By Vandana Singh

May 10, 8:06 AM

Novavax strikes co-exclusive licensing deal with Sanofi (SNY) for COVID-19 and flu-COVID-19 vaccines. Terms include upfront payment of $500M, milestone opportunities, and revenue guidance update.

NVAX

1 minute read

Evolent And Careology Form Partnership To Enhance Cancer Care In The U.S.

By Benzinga Newsdesk

May 9, 5:35 PM

Digital cancer care platform Careology and Evolent (NYSE:EVH) to offer an innovative platform to enable cancer navigationEvolent will embed Careology's digital cancer care technology within its comprehensive care

EVH